Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
Top Cited Papers
- 20 May 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (20), 1964-1965
- https://doi.org/10.1056/nejmc2105869
Abstract
Thrombosis and thrombocytopenia have been reported after vaccination with the ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca), a recombinant chimpanzee adenoviral vector encoding the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2 To date, such reactions have not been associated with other vaccines against coronavirus 2019 (Covid-19). We describe a case of extensive thrombosis associated with severe thrombocytopenia and disseminated intravascular coagulation that resembled autoimmune heparin-induced thrombocytopenia3 in a patient who had received the Ad26.COV2.S vaccine (Johnson & Johnson/Janssen), a recombinant adenovirus serotype 26 vector encoding the SARS-CoV-2 spike glycoprotein.This publication has 6 references indexed in Scilit:
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 VaccinationThe New England Journal of Medicine, 2021
- Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 VaccinationThe New England Journal of Medicine, 2021
- High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a reviewExpert Review of Hematology, 2019
- Autoimmune heparin‐induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2017